Scarica l'app Stockscreener
2.5139
0.80%
0.0239
Moleculin Biotech Inc Borsa (MBRX) Ultime notizie
Why did MBRX stock climb 14% today? - MSN
MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill
MBRX Forecast, Price Target & Analyst Ratings | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill
Moleculin Biotech files to sell 6.37M shares of common stock for holders - MSN
Moleculin Biotech Announces Annamycin Significantly Extends Survival in Preclinical Pancreatic Cancer Models at AACR 2026 - Minichart
Moleculin Highlights Promising Preclinical Data for L-ANN - TipRanks
Moleculin Biotech, Inc. Reports Promising Preclinical Results for Annamycin in Pancreatic Cancer Treatment - Quiver Quantitative
[8-K] Moleculin Biotech, Inc. Reports Material Event - Stock Titan
In pancreatic cancer models, Moleculin drug stretched survival to 29 days - Stock Titan
Moleculin Biotech, Inc. Announces Poster Presentation at ASCO 2026 Highlighting Cardiac Safety of Annamycin - Quiver Quantitative
Cancer drug heart-safety data earns Moleculin an ASCO poster slot - Stock Titan
Moleculin Biotech stock (US60855L2034): Is its oncology pipeline strong enough to drive investor ret - AD HOC NEWS
Moleculin Biotech stock (US60855L2034): Is its cancer drug pipeline strong enough to drive investor - AD HOC NEWS
Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Moleculin Biotech Stockholders Approve Warrant Share Issuance - TipRanks
Moleculin Biotech shareholders approve warrant issuance, reject name change By Investing.com - Investing.com India
Moleculin Biotech shareholders approve warrant issuance, reject name change - Investing.com
Shareholders at Moleculin (NASDAQ: MBRX) back 6.37M-share warrant plan - Stock Titan
[EFFECT] Moleculin Biotech, Inc. SEC Filing - Stock Titan
Form 10-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]: [Amend] - ADVFN
Moleculin Biotech | 10-K/A: Annual report (Amendment) - Moomoo
Moleculin Biotech (NASDAQ: MBRX) details 2025 leadership, pay and ownership - Stock Titan
Moleculin Biotech (NASDAQ: MBRX) registers 6.37M resale shares via warrants - Stock Titan
Will Moleculin Biotech Inc benefit from geopolitical trends2026 Stock Rankings & Momentum Based Trading Ideas - baoquankhu1.vn
Momentum Shift: Will Moleculin Biotech Inc benefit from geopolitical trendsStop Loss & Technical Confirmation Trade Alerts - baoquankhu1.vn
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile - Sahm
Is Moleculin Biotech (MBRX) Stock entering maturity stage | Price at $2.41, Up 3.88%Trending Social Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile - Bitget
Tangible book value per share of Moleculin Biotech, Inc. – LSE:0K2H - TradingView
Moleculin Biotech Stock: Advancing Cancer Therapies Amid Clinical Milestones and Biotech Volatility - AD HOC NEWS
MBRX Stock Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill
Meme Stocks: What are Moleculin Biotech Incs earnings expectations2026 Summary & Risk Managed Trade Strategies - baoquankhu1.vn
Total debt per share of Moleculin Biotech, Inc. – LSE:0K2H - TradingView
Moleculin Biotech Stock: Clinical-Stage Biotech Focused on Oncology Innovations for North American I - AD HOC NEWS
Moleculin Biotech (NASDAQ: MBRX) registers 6.37M resale shares tied to warrants - Stock Titan
Scalable Biotech Manufacturing Unlocks a $14B Market - Benzinga
Is Moleculin Biotech Inc undervalued by DCF analysis2026 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Sell Signal: Is Moleculin Biotech Inc undervalued by DCF analysis2026 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Moleculin at Roth Conference: Annamycin’s Market Potential By Investing.com - Investing.com Canada
Moleculin at Roth Conference: Annamycin’s Market Potential - Investing.com
MBRX: Annamycin's phase III AML trial nears key data, highlighting strong efficacy and zero cardiotoxicity - TradingView
MBRX: Annamycin's phase III AML trial nears key data, highlighting its efficacy and safety advantages - TradingView
MBRX: HC Wainwright & Co. Reiterates Buy Rating and Price Target - GuruFocus
Moleculin enrolls 45th patient in pivotal AML trial By Investing.com - Investing.com Canada
Moleculin Biotech Reports 40% Remission Rate in Early Phase 3 AML Study for Annamycin, Accelerating Toward 90 Patient Enrollment 12 - Minichart
Moleculin Biotech (MBRX) Advances Phase 2B/3 Trial for Acute Mye - GuruFocus
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout - Bitget
Moleculin Advances MIRACLE Trial, Prepares Interim AML Readout - tipranks.com
Moleculin enrolls 45th patient in pivotal AML trial - investing.com
Moleculin Biotech, Inc. Prepares for Key Interim Results in Pivotal AML Trial with 40% Early Remission Rate - Quiver Quantitative
Moleculin Hits 45-Subject Milestone, Sets Mid-2026 MIRACLE Interim Readout - TradingView
Moleculin (NASDAQ: MBRX) hits 45-subject milestone in pivotal MIRACLE AML trial - Stock Titan
0.78%
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):